Article

Accelerating manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 days

2021-12-23

Abstract excerpt

The Coalition for Epidemic Preparedness Innovations’ ‘100-day moonshot’ aspires to launch a new vaccine within 100 days of pathogen identification. Here, we describe work to optimize adenovirus vector manufacturing for rapid response, by minimizing time to clinical trial and first large-scale supply, and maximizing the output from the available manufacturing footprint. We describe a rapid viral seed expansion work...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8dabe14a-2d19-523a-abef-d13da8958337
DOI: 10.1101/2021.12.22.473478

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Accelerating manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 daysDOI 10.1101/2021.12.22.473478Read

Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic DemandSemantic proximity Read

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact componentsSemantic proximity Read

From single‐cell cloning to high‐yield influenza virus production – implementing advanced technologies in vaccine process developmentSemantic proximity Read

The Role of the Biomanufacturing Industry in Developing Diagnostics and mRNA Vaccines Against COVID-19Semantic proximity Read

The Role of the Biomanufacturing Industry in Developing Diagnostics and mRNA Vaccines Against COVID-19Semantic proximity Read

Viral vector manufacturing: how to address current and future demands?Semantic proximity Read

Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3)Semantic proximity Read

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive ReviewSemantic proximity Read

A cDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika VaccineSemantic proximity Read

From COVID-19 to Global Health: Challenges and Opportunities in mRNA Vaccine ProductionSemantic proximity Read

Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivationsSemantic proximity Read